Business Wire

MA-BLUECONIC

25.1.2024 13:59:34 CET | Business Wire | Press release

Share
VodafoneZiggo and BlueConic Win Platinum Award for Best Customer Data Platform Solution

Working with market-leading customer data platform (CDP) BlueConic, Dutch telecommunications company VodafoneZiggo has revolutionised its customer engagement strategies, resulting in a 17.6% increase in website interactions and a 4.53% reduction in churn. The collaboration has earned both companies a Platinum award for Best Customer Data Platform Solution in Juniper Research’s Future Digital Awards for Telco Innovation.

Presented by Juniper Research, the awards recognize the most innovative and disruptive telecommunications solutions operating across numerous areas. VodafoneZiggo has already won several awards for its dedication to data-driven decision-making and experimentation but knew it needed to unify its first-party customer data across numerous disparate systems and sources in order to boost engagement, deliver better customer experiences, and ultimately drive customer acquisition and retention. While some CDPs mostly focus on data unification and others tout personalization offerings, VodafoneZiggo is able to do both with BlueConic.

Leveraging the platform to understand customer preferences, easily segment their audiences, and target customers and households across channels with real-time data, VodafoneZiggo was able to transform its customer engagement strategy in several key areas:

  • Product recommendations: Using BlueConic, the conversion rate optimization (CRO) team can identify which operating system (OS) a customer is using while browsing their website. Knowing customers are likely to purchase the same type of phone again, they can personalize the shopping experience by only showing them phones with the same OS. For customers using a different OS, product recommendations dynamically update to show recently browsed devices. Within the first six months, this strategy drove a 3.5% increase in clickthrough for returning mobile visitors. On the B2B side of the business, they saw a 2.26% increase on product detail page visits and a 2.95% increase in add-to-carts. For B2C, there was a 17.6% increase in interactions for both new and returning visitors.
  • Targeting and personalization: VodafoneZiggo also leverages BlueConic to automatically send segments into custom audiences in Facebook – eliminating the need for manual uploads from their CRM system. Because segments update in real-time, ads are automatically suppressed for customers who have already purchased a new phone or renewed a subscription, thereby optimising their targeting efforts while increasing their return on ad spend (ROAS).
  • Churn prevention: By connecting churn probability scores from their Advanced Analytics department to BlueConic profiles, VodafoneZiggo can automatically route at-risk customers to chat with customer support specialists online. This strategy resulted in a 4.53% reduction in churn, a 7.14% increase in chats, and decreased web-to-call by 7.14%.

“While we’re no stranger to winning awards, it’s even more rewarding when we can share that recognition with our customers to celebrate their success,” said Ifoma Smart, VP of Global Customer Success at BlueConic. “When it comes to innovation, technology is just one part of the puzzle. You also need strong processes and a skilled and talented team – attributes VodafoneZiggo has in abundance. They quickly discovered BlueConic not only provides a better way to access and utilize first-party data to drive customer engagement but also offers the flexibility to grow with their business. We’re delighted their success with our customer data platform has been recognized by the esteemed analysts at Juniper Research.”

About Juniper Research

Juniper Research provides research and analytical services to the global hi-tech communications sector; providing consultancy, analyst reports and industry commentary.

About Juniper Research’s Future Digital Awards

Since 2008, the Future Digital Awards have honoured the companies leading innovation and disruption in their respective markets. Winners of the awards are known for developing and implementing groundbreaking products and solutions that have the potential to disrupt their ecosystem, whilst providing substantial benefits to consumers and the wider industry.

About BlueConic

BlueConic, the leading pure-play customer data platform, liberates companies’ first-party data from disparate systems and makes it accessible wherever and whenever it is required to transform customer relationships and drive business growth. Over 350 companies worldwide, including Forbes, Heineken, Mattel, Michelin, Telia Company, and VF Corp, use BlueConic to unify data into persistent, individual- profiles, and then activate it across customer touchpoints and systems in support of a wide range of growth-focused initiatives, including customer lifecycle orchestration, modeling and analytics, digital products and experiences, audience-based monetization, and more. Learn more at www.blueconic.com and follow us on Twitter and LinkedIn @BlueConic.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240125760576/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye